Erasca Insider Sells $671K as Stock Jumps 189% This Past Year

Core Insights - The insider at Erasca, Garner Ebun, significantly reduced their direct equity stake by selling 120,000 shares for approximately $670,812, as reported in an SEC filing [1][2] Transaction Summary - The transaction involved the sale of 120,000 shares at a total value of $670,800, with a post-transaction direct common stock holding of 25,076 shares valued at $129,600 [2] - The shares were sold at a weighted average purchase price of $5.59, with the market closing at the same price on January 7, 2026 [2] Company Overview - Erasca's stock price was $5.59 as of January 7, 2026, with a market capitalization of $1.77 billion and a net income of -$127.7 million over the trailing twelve months [4] - The company experienced a 1-year price change of 189.77% [4] Transaction Context - The transaction was executed through an options exercise, with no gifts or indirect transfers involved [6] - The insider's direct common stock holdings decreased by 82.72%, from 145,076 to 25,076 shares [6] - The insider retains 360,000 options outstanding, indicating potential for further exercises and sales [6] Market Context - The sale occurred during a period of significant stock appreciation, with the stock price reflecting a substantial increase over the year [6] Company Operations - Erasca focuses on developing clinical-stage therapies targeting RAS/MAPK pathway-driven cancers, with lead candidates including ERAS-007, ERAS-601, and ERAS-801 [7][8] - The company operates a research-driven business model aimed at drug discovery, clinical development, and commercialization of oncology therapeutics [7] Financial Health - Erasca reported a cash balance of $362 million, expected to fund operations into the second half of 2028, with quarterly net losses narrowing year over year [10] Investor Implications - The insider's sale, while significant, is tied to a Rule 10b5-1 plan and does not detract from the company's core thesis; key factors to monitor include upcoming Phase 1 data and the durability of the balance sheet [9][11]